EBOS Names Adam Hall as CEO, Ushering in New Growth Era

Leadership Transition Marks a New Chapter for EBOS

EBOS Group Limited has announced a significant leadership change with the retirement of its CEO, John Cullity, effective 30 June 2025. After steering the company through a transformative period marked by strategic acquisitions and robust growth, Cullity will hand over the reins to Adam Hall, a seasoned executive with a proven track record in driving operational excellence and mergers and acquisitions on a global scale.

Since becoming CEO in 2018, Cullity has been instrumental in expanding EBOS’s footprint across New Zealand, Australia, and Southeast Asia, delivering a remarkable total shareholder return of 168%. His tenure saw the company complete over 20 strategic acquisitions, including ventures into medical technology, solidifying EBOS’s position as a leader in healthcare and animal care sectors.

Adam Hall: A Strategic Choice for Growth and Innovation

Adam Hall’s appointment signals EBOS’s intent to continue its aggressive growth trajectory. Hall’s background includes senior leadership roles at Orica Limited, CF Industries, and Bunge, where he successfully led major growth initiatives and M&A transactions exceeding US$20 billion. His expertise in scaling businesses and driving innovation aligns well with EBOS’s ambitions to deepen its market presence and operational efficiency.

Hall will be based in Melbourne and assumes his role on 1 July 2025. His employment contract includes a base salary of AUD$1.35 million, with short-term and long-term incentives potentially exceeding AUD$4 million combined, reflecting the board’s confidence in his ability to deliver sustained value.

Strategic Implications and Market Outlook

The leadership change comes at a pivotal time as EBOS navigates a competitive healthcare landscape and seeks to capitalize on emerging opportunities in medical and animal care markets. The board’s emphasis on Hall’s M&A experience suggests a continued focus on inorganic growth as a key strategy.

While Cullity’s departure marks the end of a successful era, Hall’s appointment introduces fresh leadership dynamics that investors will watch closely. His ability to integrate acquisitions and foster innovation will be critical in maintaining EBOS’s momentum and shareholder confidence.

Overall, the transition appears well-managed and strategically aligned, with the board expressing strong support for Hall’s vision and leadership style.